SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/324241"
 

Search: onr:"swepub:oai:gup.ub.gu.se/324241" > Association Between...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Association Between Serum Albumin and Outcomes in Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial.

Feng, Kent Y (author)
Ambrosy, Andrew P (author)
Zhou, Zhipeng (author)
show more...
Li, Ditian (author)
Kong, Jeremy (author)
Zaroff, Jonathan G (author)
Mishell, Jacob M (author)
Ku, Ivy A (author)
Scotti, Andrea (author)
Coisne, Augustin (author)
Redfors, Björn (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
Mack, Michael J (author)
Abraham, William T (author)
Lindenfeld, JoAnn (author)
Stone, Gregg W (author)
show less...
 (creator_code:org_t)
 
show more...
 
show less...
2023-03-07
2023
English.
In: European journal of heart failure. - : Wiley. - 1879-0844 .- 1388-9842.
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Low serum albumin levels are associated with poor prognosis in numerous chronic disease states but the relationship between albumin and outcomes in patients with heart failure (HF) and secondary mitral regurgitation (SMR) has not been described.The randomized COAPT trial evaluated the safety and effectiveness of transcatheter edge-to-edge repair (TEER) with the MitraClip plus guideline-directed medical therapy (GDMT) versus GDMT alone in patients with symptomatic HF and moderate-to-severe or severe SMR. Baseline serum albumin levels were measured at enrollment. Among 614 patients enrolled in COAPT, 559 (91.0%) had available baseline serum albumin levels (median 4.0 g/dL, IQR 3.7-4.2 g/dL). Patients with albumin <4.0 g/dL compared with ≥4.0 g/dL were older and more likely to have ischemic cardiomyopathy and a hospitalization within the year prior to enrollment. After multivariable adjustment, patients with albumin <4.0 g/dL had higher 4-year rates of all-cause death (63.7% vs. 47.6%; adjusted HR 1.34, 95% CI 1.02-1.74; p=0.032), but there were no significant differences in heart failure hospitalizations (HFH) or all-cause hospitalizations according to baseline serum albumin level. The relative effectiveness of TEER plus GDMT versus GDMT alone was consistent in patients with low and high albumin levels (Pinteraction = 0.19 and 0.35 for death and HFH, respectively).Low baseline serum albumin levels were independently associated with reduced 4-year survival in patients with HF and severe SMR enrolled in the COAPT trial, but not with HFH. Patients treated with TEER derived similarly robust reductions in both death and HFH regardless of baseline albumin level. This article is protected by copyright. All rights reserved.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view